参考文献/References:
[1]Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.[2]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.[3]Herbst RS,Heymach JV,Lippman SM.Lung cancer[J].N Engl J Med,2008,359(13):1367-1380.[4]Sun CC,Li SJ,Zhang F,et al.The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression[J].Mol Ther Nucleic Acids,2016,5(11):e387.[5]Chen JH,Zhou LY,Xu S,et al.Overexpression of lncRNA HOXA11-AS promotes cell epithelial-mesenchymal transition by repressing miR-200b in non-small cell lung cancer[J].Cancer Cell Int,2017(17):64.[6]Cao X,Yeo G,Muotri AR,et al.Noncoding RNAs in the mammalian central nervous system[J].Annu Rev Neurosci,2006(29):77-103.[7]Li CH,Chen Y.Targeting long non-coding RNAs in cancers:progress and prospects[J].Int J Biochem Cell Biol,2013,45(8):1895-1910.[8]Li Y,Jiang H.Up-regulation of long non-coding RNA HOXA-AS2 in non-small cell lung cancer is associated with worse survival outcome[J].Int J Clin Exp Pathol,2017,10(9):9690-9696.[9]Zheng FX,Wang XQ,Zheng WX,et al.Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene[J].Eur Rev Med Pharmacol Sci,2019,23(11):4793-4799.[10]Jia YC,Wang JY,Liu YY,et al.LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15[J].Cell Biol Int,2019,43(4):384-393.[11]Zhao M,Xin XF,Zhang JY,et al.LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling[J].Cancer Med,2020,9(3):1196-1208.[12]Wang Z,Zhang J,Yang B,et al.Long Intergenic Noncoding RNA 00261 Acts as a Tumor Suppressor in Non-Small Cell Lung Cancer via Regulating miR-105/FHL1 Axis[J].J Cancer,2019,10(25):6414-6421.[13]Su W,Feng S,Chen X,et al.Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1,MET,and p21 in Lung Cancer[J].Cancer Res,2018,78(12):3207-3219.[14]Cai Y,Dong ZY,Wang JY.LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway[J].Eur Rev Med Pharmacol Sci,2018,22(15):4879-4887.[15]Lin S,Zhang R,An X,et al.LncRNA HOXA-AS3 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells[J].Oncogenesis,2019,8(11):60.[16]Zhao X,Li X,Zhou L,et al.LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3[J].Cancer Sci,2018,109(10):3068-3079.[17]Ma G,Zhu J,Liu F,et al.Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p[J].DNA Cell Biol,2019,38(2):176-183.[18]Wang Z,Pan L,Yu H,et al.The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis[J].Biosci Rep,2018,38(4):BSR20180400.[19]Santos JC,Ribeiro ML,Sarian LO,et al.Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation[J].Am J Cancer Res,2016,6(10):2129-2139.[20]Lei Y,Guo W,Chen B,et al.Tumorreleased lncRNA H19 promotes gefitinib resistance via packaging into exosomes in nonsmall cell lung cancer[J].Oncol Rep,2018,40(6):3438-3446.[21]Wu D,Li Y,Zhang H,et al.Knockdown of Lncrna PVT1 Enhances Radiosensitivity in Non-Small Cell Lung Cancer by Sponging Mir-195[J].Cellular Physiology and Biochemistry,2017,42(6):2453-2466.[22]Chen L,Ren P,Zhang Y,et al.Long noncoding RNA GAS5 increases the radiosensitivity of A549 cells through interaction with the miR21/PTEN/Akt axis[J].Oncol Rep,2020,43(3):897-907.[23]Yang QS,Li B,Xu G,et al.Long noncoding RNA LINC00483/microRNA-144 regulates radiosensitivity and epithelial-mesenchymal transition in lung adenocarcinoma by interacting with HOXA10[J].J Cell Physiol,2019,234(7):11805-11821.[24]Liu AM,Zhu Y,Huang ZW,et al.Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370[J].Eur Rev Med Pharmacol Sci,2019,23(13):5802-5814.[25]Yu Z,Wang G,Zhang C,et al.LncRNA SBF2-AS1 affects the radiosensitivity of non-small cell lung cancer via modulating microRNA-302a/MBNL3 axis[J].Cell Cycle,2020,19(3):300-316.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(12):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(12):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(12):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(12):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]杨宵月,李建伟.LncRNA调控人类疾病关系数据库的研究[J].医学信息,2019,32(12):28.[doi:10.3969/j.issn.1006-1959.2019.12.010]
YANG Xiao-yue,LI Jian-wei.LncRNA Regulation of Human Disease Relationship Database[J].Medical Information,2019,32(12):28.[doi:10.3969/j.issn.1006-1959.2019.12.010]
[7]张天竺,宁 勇.长链非编码RNA调控乳腺癌发生发展的研究进展[J].医学信息,2019,32(12):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
ZHANG Tian-zhu,NING Yong.Advances in Research on Long-chain Non-coding RNA Regulation of Breast Cancer Development[J].Medical Information,2019,32(12):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
[8]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(12):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[9]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(12):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[10]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]